What is HC Wainwright’s Estimate for RCUS FY2030 Earnings?

Arcus Biosciences, Inc. (NYSE:RCUS) – HC Wainwright issued their FY2030 earnings estimates for Arcus Biosciences in a research report issued to clients and investors on Thursday, February 26th. HC Wainwright analyst E. Bodnar expects that the company will earn $0.30 per share for the year. HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share.

A number of other research analysts also recently commented on RCUS. Wells Fargo & Company set a $23.00 price objective on Arcus Biosciences and gave the stock an “equal weight” rating in a research note on Thursday, February 12th. Truist Financial set a $30.00 price target on shares of Arcus Biosciences in a report on Friday, December 12th. Bank of America upped their price target on shares of Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a research report on Friday, November 28th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $20.00 price objective (down from $23.00) on shares of Arcus Biosciences in a report on Thursday, January 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Wednesday, January 21st. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Arcus Biosciences presently has an average rating of “Moderate Buy” and an average price target of $29.33.

Arcus Biosciences Stock Up 4.2%

Shares of Arcus Biosciences stock opened at $20.36 on Friday. The stock has a market capitalization of $2.55 billion, a price-to-earnings ratio of -6.17 and a beta of 0.84. Arcus Biosciences has a twelve month low of $6.50 and a twelve month high of $26.40. The company has a current ratio of 3.65, a quick ratio of 3.65 and a debt-to-equity ratio of 0.22. The business’s 50 day simple moving average is $21.57 and its 200-day simple moving average is $18.44.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Wednesday, February 25th. The company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.22. The company had revenue of $33.00 million during the quarter, compared to the consensus estimate of $24.94 million. Arcus Biosciences had a negative return on equity of 69.86% and a negative net margin of 142.91%.Arcus Biosciences’s quarterly revenue was down 8.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.03) earnings per share.

Insiders Place Their Bets

In related news, CAO Alexander Azoy sold 4,343 shares of the stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $22.25, for a total value of $96,631.75. Following the completion of the transaction, the chief accounting officer owned 18,531 shares in the company, valued at $412,314.75. This represents a 18.99% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, President Juan C. Jaen sold 31,823 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $21.41, for a total transaction of $681,330.43. Following the transaction, the president directly owned 922,240 shares in the company, valued at approximately $19,745,158.40. The trade was a 3.34% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 263,987 shares of company stock valued at $6,025,620. Corporate insiders own 9.60% of the company’s stock.

Institutional Investors Weigh In On Arcus Biosciences

Institutional investors have recently added to or reduced their stakes in the company. Hantz Financial Services Inc. boosted its stake in Arcus Biosciences by 121.9% during the 4th quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after purchasing an additional 881 shares in the last quarter. T. Rowe Price Investment Management Inc. bought a new position in Arcus Biosciences during the fourth quarter valued at about $39,000. GAMMA Investing LLC boosted its stake in Arcus Biosciences by 59.1% during the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock valued at $37,000 after buying an additional 1,021 shares in the last quarter. SBI Securities Co. Ltd. grew its holdings in Arcus Biosciences by 13,547.6% during the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock worth $39,000 after acquiring an additional 2,845 shares during the period. Finally, Abich Financial Wealth Management LLC bought a new stake in Arcus Biosciences in the third quarter worth about $69,000. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.